WallStSmart

Alto Neuroscience, Inc. (ANRO)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 8.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).

ANRO

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.0
Piotroski: 2/9Altman Z: 1.17

ONC

Buy

54

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 5.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ANRO.

ONCUndervalued (+81.1%)

Margin of Safety

+81.1%

Fair Value

$1857.02

Current Price

$322.08

$1534.94 discount

UndervaluedFair: $1857.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANRO1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

ONC3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
35.5%10/10

Revenue surging 35.5% year-over-year

EPS GrowthGrowth
16971.0%10/10

Earnings expanding 16971.0% YoY

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Areas to Watch

ANRO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$955.61M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
74.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ANRO

The strongest argument for ANRO centers on Debt/Equity.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.

Bear Case : ANRO

The primary concerns for ANRO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.

Key Dynamics to Monitor

ANRO profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.

ANRO carries more volatility with a beta of 1.07 — expect wider price swings.

ONC is growing revenue faster at 35.5% — sustainability is the question.

ONC generates stronger free cash flow (161M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (54/100 vs 26/100) and 35.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alto Neuroscience, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company is headquartered in Los Altos, California.

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?